A ketogenic diet attenuates proliferation and stemness of glioma stem‑like cells by altering metabolism resulting in increased ROS production

Ji,Chen‑Chen; Hu,Yi‑Yang; Cheng,Guang; Liang,Liang; Gao,Bo; Ren,Ying‑Peng; Liu,Jin‑Tao; Cao,Xiu‑Li; Zheng,Min‑Hua; Li,San‑Zhong; Wan,Feng; Han,Hua; Fei,Zhou

doi:10.3892/ijo.2019.4942

A ketogenic diet attenuates proliferation and stemness of glioma stem‑like cells by altering metabolism resulting in increased ROS production

Authors:
- Chen‑Chen Ji
- Yi‑Yang Hu
- Guang Cheng
- Liang Liang
- Bo Gao
- Ying‑Peng Ren
- Jin‑Tao Liu
- Xiu‑Li Cao
- Min‑Hua Zheng
- San‑Zhong Li
- Feng Wan
- Hua Han
- Zhou Fei
View Affiliations

Affiliations: Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, State Key Laboratory of Cancer Biology, Department of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, Department of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China, Department of Orthopedic Surgery, 413 Hospital, Zhoushan, Zhejiang 316000, P.R. China, Department of Neurosurgery, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: December 13, 2019 https://doi.org/10.3892/ijo.2019.4942
Pages: 606-617

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Abnormal metabolism serves a critical role in the development and progression of different types of malignancies including glioblastoma (GBM), and may therefore serve as a promising target for treatment of cancer. Preclinical studies have indicated that a ketogenic diet (KD) may exhibit beneficial effects in patients with GBM; however, the underlying mechanisms remain incompletely understood. The aim of the present study was to evaluate the effects of a KD on glioma stem‑like cells (GSCs), by culturing patient‑derived primary GSCs as well as a GSC cell line in glucose‑restricted, β‑hydroxybutyrate‑containing medium (BHB‑Glow) which was used to mimic clinical KD treatment. GSCs cultured in BHB‑Glow medium exhibited reduced proliferation and increased apoptosis compared with cells grown in the control medium. Furthermore, decreased expression of stem cell markers, diminished self‑renewal in vitro, and reduced tumorigenic capacity in vivo, providing evidence that the stemness of GSCs was compromised. Mechanistically, culturing in BHB‑Glow medium reduced glucose uptake and inhibited glycolysis in GSCs. Furthermore, culturing in the BHB‑Glow medium resulted in morphological and functional disturbances to the mitochondria of GSCs. These metabolic changes may have reduced ATP production, promoted lactic acid accumulation, and thus, increased the production of reactive oxygen species (ROS) in GSCs. The expression levels and activation of mammalian target of rapamycin, hypoxia‑inducible factor 1 and B‑cell lymphoma 2 were decreased, consistent with the reduced proliferation of GSCs in BHB‑Glow medium. ROS scavenging reversed the inhibitory effects of a KD on GSCs. Taken together, the results demonstrate that treatment with KD inhibited proliferation of GSCs, increased apoptosis and attenuated the stemness in GSCs by increasing ROS production.

View Figures

View References

1	Poteet E, Choudhury GR, Winters A, Li W, Ryou MG, Liu R, Tang L, Ghorpade A, Wen Y, Yuan F, et al: Reversing the Warburg effect as a treatment for glioblastoma. J Biol Chem. 288:9153–9164. 2013. View Article : Google Scholar : PubMed/NCBI
2	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
3	Maurer GD, Brucker DP, Bähr O, Harter PN, Hattingen E, Walenta S, Mueller-Klieser W, Steinbach JP and Rieger J: Differential utilization of ketone bodies by neurons and glioma cell lines: A rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 11:3152011. View Article : Google Scholar : PubMed/NCBI
4	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
5	Seyfried TN, Flores R, Poff AM, D’Agostino DP and Mukherjee P: Metabolic therapy: A new paradigm for managing malignant brain cancer. Cancer Lett. 356:289–300. 2015. View Article : Google Scholar
6	Hoskin PJ, Sibtain A, Daley FM and Wilson GD: GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: Relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer. 89:1290–1297. 2003. View Article : Google Scholar : PubMed/NCBI
7	Ward PS and Thompson CB: Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell. 21:297–308. 2012. View Article : Google Scholar : PubMed/NCBI
8	Shen YA, Wang CY, Hsieh YT, Chen YJ and Wei YH: Metabolic reprogramming orchestrates cancer stem cell properties in naso-pharyngeal carcinoma. Cell Cycle. 14:86–98. 2015. View Article : Google Scholar
9	Klement RJ, Bandyopadhyay PS, Champ CE and Walach H: Application of Bayesian evidence synthesis to modelling the effect of ketogenic therapy on survival of high grade glioma patients. Theor Biol Med Model. 15:122018. View Article : Google Scholar : PubMed/NCBI
10	Augur ZM, Doyle CM, Li M, Mukherjee P and Seyfried TN: Nontoxic targeting of energy metabolism in preclinical VM-M3 experimental glioblastoma. Front Nutr. 5:912018. View Article : Google Scholar : PubMed/NCBI
11	Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, Glass J, Kim L and Shi W: Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol. 117:125–131. 2014. View Article : Google Scholar : PubMed/NCBI
12	Martuscello RT, Vedam-Mai V, McCarthy DJ, Schmoll ME, Jundi MA, Louviere CD, Griffith BG, Skinner CL, Suslov O, Deleyrolle LP and Reynolds BA: A supplemented high-fat low-carbohydrate diet for the treatment of glioblastoma. Clin Cancer Res. 22:2482–2495. 2016. View Article : Google Scholar
13	Poff A, Koutnik AP, Egan KM, Sahebjam S, D’Agostino D and Kumar NB: Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma. Semin Cancer Biol. 56:135–148. 2017. View Article : Google Scholar
14	Ito K and Suda T: Metabolic requirements for the maintenance of self-renewing stem cells. Nat Rev Mol Cell Biol. 15:243–256. 2014. View Article : Google Scholar : PubMed/NCBI
15	Sell S: On the stem cell origin of cancer. Am J Pathol. 176:2584–2594. 2010. View Article : Google Scholar : PubMed/NCBI
16	Batlle E and Clevers H: Cancer stem cells revisited. Nat Med. 23:1124–1134. 2017. View Article : Google Scholar : PubMed/NCBI
17	Folmes CD, Dzeja PP, Nelson TJ and Terzic A: Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell. 11:596–606. 2012. View Article : Google Scholar : PubMed/NCBI
18	Nakano I: Therapeutic potential of targeting glucose metabolism in glioma stem cells. Expert Opin Ther Targets. 18:1233–1236. 2014. View Article : Google Scholar : PubMed/NCBI
19	Cairns RA, Harris IS and Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95. 2011. View Article : Google Scholar : PubMed/NCBI
20	Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, Weil RJ, Nakano I, Sarkaria JN, Stringer BW, et al: Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci. 16:1373–1382. 2013. View Article : Google Scholar : PubMed/NCBI
21	Agnihotri S and Zadeh G: Metabolic reprogramming in glioblastoma: The influence of cancer metabolism on epigenetics and unanswered questions. Neuro Oncol. 18:160–172. 2016. View Article : Google Scholar :
22	Zhou Y, Zhou Y, Shingu T, Feng L, Chen Z, Ogasawara M, Keating MJ, Kondo S and Huang P: Metabolic alterations in highly tumorigenic glioblastoma cells: Preference for hypoxia and high dependency on glycolysis. J Biol Chem. 286:32843–32853. 2011. View Article : Google Scholar : PubMed/NCBI
23	Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE, Ahmadi R, Lohr J, Dictus C, Gdynia G, et al: Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res. 16:2715–2728. 2010. View Article : Google Scholar : PubMed/NCBI
24	Gao F, Zhang YF, Zhang ZP, Fu LA, Cao XL, Zhang YZ, Guo CJ, Yan XC, Yang QC, Hu YY, et al: miR-342-5p regulates neural stem cell proliferation and differentiation downstream to Notch signaling in mice. Stem Cell Reports. 8:1032–1045. 2017. View Article : Google Scholar : PubMed/NCBI
25	Hu YY, Fu LA, Li SZ, Chen Y, Li JC, Han J, Liang L, Li L, Ji CC, Zheng MH and Han H: Hif-1α and Hif-2α differentially regulate Notch signaling through competitive interaction with the intracellular domain of Notch receptors in glioma stem cells. Cancer Lett. 349:67–76. 2014. View Article : Google Scholar : PubMed/NCBI
26	Ilkhanizadeh S and Weiss WA: Starvation favors glioma stem cells. Nat Neurosci. 16:1359–1361. 2013. View Article : Google Scholar : PubMed/NCBI
27	Bassoy EY, Kasahara A, Chiusolo V, Jacquemin G, Boydell E, Zamorano S, Riccadonna C, Pellegatta S, Hulo N, Dutoit V, et al: ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells. EMBO J. 36:1493–1512. 2017. View Article : Google Scholar : PubMed/NCBI
28	Halabe Bucay A: The biological significance of cancer: Mitochondria as a cause of cancer and the inhibition of glycolysis with citrate as a cancer treatment. Med Hypotheses. 69:826–828. 2007. View Article : Google Scholar : PubMed/NCBI
29	Mischel PS: HOT Models in flux: Mitochondrial glucose oxidation fuels glioblastoma growth. Cell Metab. 15:789–790. 2012. View Article : Google Scholar : PubMed/NCBI
30	Bernini A, Masoodi M, Solari D, Miroz JP, Carteron L, Christinat N, Morelli P, Beaumont M, Abed-Maillard S, Hartweg M, et al: Modulation of cerebral ketone metabolism following traumatic brain injury in humans. J Cereb Blood Flow Metab. October 24–2018.Epub ahead of print. PubMed/NCBI
31	Fusco S, Leone L, Barbati SA, Samengo D, Piacentini R, Maulucci G, Toietta G, Spinelli M, McBurney M, Pani G and Grassi C: A CREB-Sirt1-Hes1 circuitry mediates neural stem cell response to glucose availability. Cell Rep. 14:1195–1205. 2016. View Article : Google Scholar : PubMed/NCBI
32	Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kämmerer U, Coy JF, Weller M and Steinbach JP: ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 44:1843–1852. 2014. View Article : Google Scholar : PubMed/NCBI
33	Woolf EC, Curley KL, Liu Q, Turner GH, Charlton JA, Preul MC and Scheck AC: The ketogenic diet alters the hypoxic response and affects expression of proteins associated with angiogenesis, invasive potential and vascular permeability in a mouse glioma model. PLoS One. 10:e1303572015. View Article : Google Scholar
34	Klement RJ and Champ CE: Calories, carbohydrates, and cancer therapy with radiation: Exploiting the five R’s through dietary manipulation. Cancer Metastasis Rev. 33:217–229. 2014. View Article : Google Scholar : PubMed/NCBI
35	Venneti S and Thompson CB: Metabolic modulation of epigenetics in gliomas. Brain Pathol. 23:217–221. 2013. View Article : Google Scholar : PubMed/NCBI
36	Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, McAllister S and Soroceanu L: Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. Cell Death Dis. 6:e16012015. View Article : Google Scholar : PubMed/NCBI
37	Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, Pai MY, Li S, Ta L, Fazlollahi F, et al: 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. Cell Metab. 22:508–515. 2015. View Article : Google Scholar : PubMed/NCBI
38	Sharma PK, Bhardwaj R, Dwarakanath BS and Varshney R: Metabolic oxidative stress induced by a combination of 2-DG and 6-AN enhances radiation damage selectively in malignant cells via non-coordinated expression of antioxidant enzymes. Cancer Lett. 295:154–166. 2010. View Article : Google Scholar : PubMed/NCBI
39	Zhao Y, Hu X, Liu Y, Dong S, Wen Z, He W, Zhang S, Huang Q and Shi M: ROS signaling under metabolic stress: Cross-talk between AMPK and AKT pathway. Mol Cancer. 16:792017. View Article : Google Scholar : PubMed/NCBI
40	Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD, et al: Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 339:211–214. 2013. View Article : Google Scholar
41	Benjamin JS, Pilarowski GO, Carosso GA, Zhang L, Huso DL, Goff LA, Vernon HJ, Hansen KD and Bjornsson HT: A keto-genic diet rescues hippocampal memory defects in a mouse model of Kabuki syndrome. Proc Natl Acad Sci USA. 114:125–130. 2017. View Article : Google Scholar
42	Poff AM, Ari C, Arnold P, Seyfried TN and D’Agostino DP: Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer. Int J Cancer. 135:1711–1720. 2014. View Article : Google Scholar : PubMed/NCBI
43	Chung H and Park YK: Rationale, feasibility and acceptability of ketogenic diet for cancer treatment. J Cancer Prev. 22:127–134. 2017. View Article : Google Scholar : PubMed/NCBI